Overview
- The Health Ministry issued a draft gazette notification on Nov. 6 that would add ‘antimicrobials’ to the New Drugs and Clinical Trials Rules, 2019 so manufacturers must obtain permission from the Central Licensing Authority before applying for a state manufacturing licence.
- The draft says the move responds to gaps in state licensing where required studies such as bioavailability, bioequivalence and stability were not consistently demanded, which the ministry says can allow substandard products to contribute to antimicrobial resistance.
- Separate amendments to the Drugs Rules, 1945 would create distinct wholesale forms (Form 19-BC and Form 20-BC) and require wholesalers of bulk drugs to operate under a named competent person, with categories to include substances regulated under the NDPS Act.
- In a companion draft the ministry proposes targeted exemptions from parts of the revised Schedule M for makers of medicinal gases, empty gelatin capsules and disinfectant fluids so regulators can apply product-specific requirements without lowering safety standards.
- The proposals are at the draft stage and open for 30 days of public comment, after which the Centre will decide on final rules; if adopted the changes aim to create uniform central oversight but could lengthen approval steps for manufacturers and alter how states issue licences.